Your browser doesn't support javascript.
loading
Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth, J D; Burris, H A; Morrissey, L H; Thomas, M; Erland, J B; Butts, J A; Joseph, G; Kalman, L; Greco, F A.
Afiliación
  • Hainsworth JD; Sarah Cannon-Minnie Pearl Cancer Center, Nashville, Tennessee 37202, USA.
Cancer J ; 6(3): 151-6, 2000.
Article en En | MEDLINE | ID: mdl-10882330
PURPOSE: To evaluate the feasibility, toxicity, and efficacy of adding vinorelbine to the paclitaxel/carboplatin combination in the treatment of advanced non-small cell lung cancer. PATIENTS AND METHODS: Patients with advanced (stage IIIB/IV) non-small cell lung cancer who had received no previous chemotherapy were treated with the following three-drug regimen: paclitaxel, 200 mg/m2, 1-hour i.v. infusion, day 1; carboplatin, AUC 6.0 i.v., day 1; and vinorelbine, 22.5 mg/m2 i.v. days 1 and either 8 or 15. Treatment was repeated every 21 days. This phase II trial was conducted in a multicenter, community-based setting. RESULTS: Eighty-nine patients were treated with a median of four courses of therapy (range, one to eight). Thirty-one patients (35%) had major responses (two complete, 29 partial), and 36 patients (40%) had a minor response or stable disease. Actuarial median survival was 8.6 months; 1 year survival was 43%. Leukopenia was the major toxicity: 73% of patients had grade 3/4 toxicity, and 32 patients (36%) were hospitalized for neutropenia/fever (11% of total courses administered). Treatment-related death due to infection occurred in four patients (4%). CONCLUSIONS: This three-drug regimen is feasible and efficacious in the treatment of advanced non-small cell lung cancer. The addition of vinorelbine increases the incidence of severe leukopenia substantially when compared with the paclitaxel/carboplatin regimen. However, other toxicities are not markedly increased. Ongoing randomized trials will define the role of this regimen in the treatment of non-small cell lung cancer.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vinblastina / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatino / Paclitaxel / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Antineoplásicos / Antineoplásicos Fitogénicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer J Asunto de la revista: NEOPLASIAS Año: 2000 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vinblastina / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatino / Paclitaxel / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Antineoplásicos / Antineoplásicos Fitogénicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer J Asunto de la revista: NEOPLASIAS Año: 2000 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos